The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...

By increasing neuroplasticity, psychedelics may both enhance creativity and be useful for treating a variety of psychiatric ...

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

Northeastern University researchers have made a breakthrough drug discovery, developing the first synthetic endogenous ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

T cell immunotherapies are on the cutting-edge of cancer treatments, but a full understanding of how they work has been ...

When laboratory mice suffer brain damage, e.g., from an injection, research group leader Jan Deussing has observed that a ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Under the TCR-antigen data licensing agreement, Adaptive will receive an upfront payment and additional future potential annual licensing fees under this non-exclusive, multi-year data access ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...